ResMed Inc. (NYSE:RMD) Shares Sold by Aspiriant LLC

Aspiriant LLC decreased its position in ResMed Inc. (NYSE:RMD) by 5.5% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,205 shares of the medical equipment provider’s stock after selling 70 shares during the quarter. Aspiriant LLC’s holdings in ResMed were worth $294,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in RMD. UMB Bank n.a. raised its stake in ResMed by 1.9% during the third quarter. UMB Bank n.a. now owns 2,465 shares of the medical equipment provider’s stock worth $602,000 after acquiring an additional 47 shares during the period. Dorsey & Whitney Trust CO LLC raised its position in shares of ResMed by 3.7% during the 1st quarter. Dorsey & Whitney Trust CO LLC now owns 1,473 shares of the medical equipment provider’s stock worth $292,000 after purchasing an additional 52 shares during the period. QRG Capital Management Inc. lifted its holdings in shares of ResMed by 4.5% in the 2nd quarter. QRG Capital Management Inc. now owns 1,291 shares of the medical equipment provider’s stock worth $247,000 after purchasing an additional 56 shares during the last quarter. Inspire Advisors LLC boosted its position in ResMed by 1.9% during the 2nd quarter. Inspire Advisors LLC now owns 3,060 shares of the medical equipment provider’s stock valued at $586,000 after purchasing an additional 56 shares during the period. Finally, Envestnet Portfolio Solutions Inc. grew its stake in ResMed by 1.9% during the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 3,188 shares of the medical equipment provider’s stock worth $631,000 after buying an additional 60 shares during the last quarter. 54.98% of the stock is currently owned by institutional investors.

Insider Activity

In related news, General Counsel Michael J. Rider sold 882 shares of ResMed stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $231.00, for a total value of $203,742.00. Following the transaction, the general counsel now directly owns 10,512 shares in the company, valued at $2,428,272. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, General Counsel Michael J. Rider sold 882 shares of the stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $231.00, for a total value of $203,742.00. Following the completion of the transaction, the general counsel now owns 10,512 shares in the company, valued at $2,428,272. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Kaushik Ghoshal sold 4,260 shares of the business’s stock in a transaction dated Friday, October 11th. The stock was sold at an average price of $238.48, for a total value of $1,015,924.80. Following the sale, the insider now owns 21,788 shares in the company, valued at approximately $5,196,002.24. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 123,874 shares of company stock worth $28,151,142. Insiders own 0.71% of the company’s stock.

ResMed Stock Up 0.2 %

Shares of RMD stock opened at $240.00 on Friday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.69 and a current ratio of 2.59. The stock has a market cap of $35.22 billion, a PE ratio of 34.63, a price-to-earnings-growth ratio of 2.17 and a beta of 0.69. The business’s fifty day moving average is $238.78 and its 200-day moving average is $215.88. ResMed Inc. has a 1 year low of $132.24 and a 1 year high of $255.18.

ResMed (NYSE:RMD) last issued its quarterly earnings results on Thursday, August 1st. The medical equipment provider reported $2.08 EPS for the quarter, topping the consensus estimate of $2.03 by $0.05. ResMed had a net margin of 21.79% and a return on equity of 25.00%. The firm had revenue of $1.20 billion for the quarter, compared to analysts’ expectations of $1.22 billion. During the same period in the previous year, the business earned $1.60 earnings per share. ResMed’s revenue for the quarter was up 6.9% compared to the same quarter last year. Equities analysts expect that ResMed Inc. will post 9.02 earnings per share for the current fiscal year.

ResMed Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, September 19th. Shareholders of record on Thursday, August 15th were issued a $0.53 dividend. The ex-dividend date was Thursday, August 15th. This represents a $2.12 annualized dividend and a dividend yield of 0.88%. This is a boost from ResMed’s previous quarterly dividend of $0.48. ResMed’s dividend payout ratio is currently 30.59%.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. Bank of America raised their target price on ResMed from $240.00 to $270.00 and gave the company a “buy” rating in a research note on Thursday, September 26th. Citigroup lowered shares of ResMed from a “buy” rating to a “neutral” rating in a research note on Monday, June 24th. Oppenheimer lowered shares of ResMed from an “outperform” rating to a “market perform” rating in a research note on Tuesday, June 25th. Needham & Company LLC reiterated a “hold” rating on shares of ResMed in a research report on Tuesday, October 1st. Finally, Royal Bank of Canada increased their price objective on ResMed from $206.00 to $224.00 and gave the stock a “sector perform” rating in a report on Tuesday, October 1st. One research analyst has rated the stock with a sell rating, five have issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $218.18.

ResMed Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.